Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Cannabis Use Disorder
NCT07879612Phase 2Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2027
- Primary completion
- Jan 2029
01
Overview
A Phase 2 trial of semaglutide in cannabis use disorder (CUD), sponsored by Massachusetts General Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT07879612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879612.